MedPath

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 3
Active, not recruiting
Conditions
Gastric Cancer
Interventions
Registration Number
NCT05144854
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Brief Summary

This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
626
Inclusion Criteria
  1. Participants with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) that has been histologically confirmed to be predominant adenocarcinoma
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0 or 1
  3. Participants who have a life expectancy of at least 3 months
Exclusion Criteria
  1. Participants with a history or complications of multiple cancers
  2. Participants with a complication or history of severe hypersensitivity to any other antibody products
  3. Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ONO-4538 + ipilimumab + chemotherapyONO-4538-
ONO-4538 + ipilimumab + chemotherapyIpilimumab-
ONO-4538 + ipilimumab + chemotherapyS-1-
ChemotherapyOxaliplatin-
ChemotherapyCapecitabine-
ONO-4538 + ipilimumab + chemotherapyOxaliplatin-
ONO-4538 + ipilimumab + chemotherapyCapecitabine-
ChemotherapyS-1-
Primary Outcome Measures
NameTimeMethod
Overall survival (OS)up to 3 years
Secondary Outcome Measures
NameTimeMethod
Objective response rate (ORR) (site investigator assessment)up to 3 years
Best overall response (BOR) (site investigator assessment)up to 3 years
Progression-free survival (PFS) (site investigator assessment)up to 3 years
Duration of response (DOR) (site investigator assessment)up to 3 years
Time to response (TTR) (site investigator assessment)up to 3 years
Adverse eventUp to 30 days after the last dose
Disease control rate (DCR) (site investigator assessment)up to 3 years
Progression-free survival after the next line of therapy (PFS2) (site investigator assessment)up to 3 years
Maximum percent change in the sum diameters of the target lesions (site investigator assessment)up to 3 years

Trial Locations

Locations (57)

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo

🇯🇵

Minato-ku, Tokyo, Japan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

National Cancer Center Hospital

🇯🇵

Chuo-ku, Tokyo, Japan

Taipei Medical University Hospital

🇨🇳

Taipei City, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

Osaki Citizen Hospital

🇯🇵

Osaki-shi, Miyagi, Japan

Kanagawa Cancer Center

🇯🇵

Yokohama-shi, Kanagawa, Japan

University of Tokyo Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Osaka University Hospital

🇯🇵

Suita-shi, Osaka, Japan

Saitama Medical University International Medical Center

🇯🇵

Hidaka-shi, Saitama, Japan

Hallym University Sacred Heart Hospital

🇰🇷

Anyang-si, Gyeonggi-do, Korea, Republic of

Kosin University Gospel Hospital

🇰🇷

Busan, Gangwon-do, Korea, Republic of

National Cancer Center

🇰🇷

Goyang-si, Gyeonggi-do, Korea, Republic of

Chonnam National University Hwasun Hospital

🇰🇷

Hwasun-gun, Jeollanam-do, Korea, Republic of

Jeonbuk national university hospital

🇰🇷

Jeonju-si, Jeollabuk-do, Korea, Republic of

Dong-A University Hospital

🇰🇷

Busan, Korea, Republic of

Keimyung University Dongsan Hospital

🇰🇷

Daegu, Korea, Republic of

Gachon University Gil Medical Center

🇰🇷

Incheon, Korea, Republic of

Konyang University Hospital

🇰🇷

Daejeon, Korea, Republic of

Gangnam Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Chi Mei Hospital, Liouying

🇨🇳

Tainan, Taiwan

Far Eastern Memorial Hospital

🇨🇳

New Taipei City, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center

🇨🇳

Taipei, Taiwan

Chang Gung Memorial Hospital,Linkou

🇨🇳

Taoyuan County, Taiwan

Tri-Service General Hospital

🇨🇳

Taipei, Taiwan

National Cancer Center Hospital East

🇯🇵

Kashiwa-shi, Chiba, Japan

Saitama Cancer Center

🇯🇵

Ina-machi, Kitaadati-gun, Saitama, Japan

Shizuoka Cancer Center

🇯🇵

Nagaizumi-Cho, Sunto-Gun, Shizuoka, Japan

Cancer Institute Hospital of JFCR

🇯🇵

Koto-ku, Tokyo, Japan

Keio University Hospital

🇯🇵

Shinjyuku-ku, Tokyo, Japan

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Gyeonggi-do, Korea, Republic of

The Catholic University of Korea, St. Vincent's Hospital

🇰🇷

Suwon-si, Gyeonggi-do, Korea, Republic of

Ajou University Hospital

🇰🇷

Suwon, Gyeonggi-do, Korea, Republic of

Inje University Haeundae Paik Hospital

🇰🇷

Busan, Korea, Republic of

Pusan National University Hospital

🇰🇷

Busan, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Chung-Ang University Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Chang Gung Memorial Hospital, Keelung

🇨🇳

Keelung City, Taiwan

Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare

🇨🇳

New Taipei City, Taiwan

Taipei Municipal Wanfang Hospital Managed by Taipei Medical University

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Chungbuk National University Hospital

🇰🇷

Cheongju-si, Chungcheongbuk-do, Korea, Republic of

Ulsan University Hospital

🇰🇷

Ulsan, Korea, Republic of

CHA Bundang Medical Center, CHA University

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Kyungpook National University Chilgok Hospital

🇰🇷

Daegu, Gyeongsangbuk-do, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan-si, Gyeongsangnam-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath